16th Annual BIO CEO & Investor Conference to Feature Fireside Chats Between Biopharma CEOs and Wall Street Analysts

BIO announced this year&rsquo;s Fireside Chats lineup for the 16<sup>th</sup>&nbsp;annual BIO CEO &amp; Investor Conference. The chats will feature a set of candid, one-on-one conversations between biopharma leaders and analysts, followed by an interactive question and answer session.&nbsp;</p>

WASHINGTON, D.C. (December 12, 2013) – The Biotechnology Industry Organization (BIO) today announced this year’s Fireside Chats lineup for the 16th annual BIO CEO & Investor Conference. The chats will feature a set of candid, one-on-one conversations between biopharma leaders and analysts, followed by an interactive question and answer session. The event, to be held in New York City, February 10-11, 2014, is the largest investor conference focused on established and emerging publicly traded and select private biotech companies.

“We’ve just experienced one of the busiest years in the history of the biotech sector,” said BIO president & CEO Jim Greenwood. “With more than 30 IPOs and surprisingly strong performances from biotech stocks, industry insiders and observers alike are eager to know what’s next. As the first major East Coast biotech event of the year, the 2014 BIO CEO & Investor Conference will be the place for industry executives and investors to exchange valuable insights on what we can expect over the coming year.”

The five CEO’s participating in the 2014 Fireside Chats are made up of the industry’s top leaders from the top firms. The complete list of participants includes:

Leonard Bell, M.D., Chief Executive Officer, Alexion Pharmaceuticals, Inc.

Leonard Bell, M.D. is the Chief Executive Officer and principal founder of Alexion Pharmaceuticals. Under his continuous leadership since 1992, when he started the firm, Alexion has become a fast-growing and profitable global biopharmaceutical company, with more than 1,600 employees serving patients in 50 countries through fully integrated research, discovery, development, manufacturing and commercial capabilities.

Belen Garigo, M.D., President and CEO, Merck Serono

Belén Garijo, MD, is President and CEO of Merck Serono as well as a member of the Pharmaceutical Executive Committee.

Prior to joining Merck KGaA, Darmstadt, Germany, Dr. Garijo was Senior Vice President, Global Operations Region Europe at Paris based Sanofi and served as Global Integration Leader for the Genzyme integration.

Belén Garijo began her career at Abbott Laboratories as Medical Director of its Spanish affiliate before moving to the US to head Global Medical Affairs at Abbott headquarters in Illinois.

Richard F. Pops, Chairman & Chief Executive Officer, Alkermes plc

Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 1,200 employees and a portfolio of more than 20 commercial products.

David E.I. Pyott, Chairman of the Board & Chief Executive Officer, Allergan

David E.I. Pyott joined Allergan on January 1, 1998. During his tenure, Mr. Pyott has transformed Allergan from a small eye care business to a global specialty pharmaceutical and medical device company with leadership positions in six medical specialties. Allergan is currently the fastest growing global ophthalmic company and holds leadership positions in other specialty areas including neurosciences, medical aesthetics and medical dermatology.

Christopher A. Viehbacher, Chief Executive Officer, Sanofi, Chairman, Genzyme, President of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Christopher started his career in finance at PriceWaterhouseCoopers and joined GlaxoSmithKline (GSK) in 1988. Throughout the next 20 years with the company, he acquired broad international experience in Europe, in the United States and in Canada. His last position, before joining Sanofi was President, Pharmaceutical Operations North America. He was also a member of the board and Co-Chairman of the Portfolio Management Board.

Christopher was elected President of the EFPIA (European Federation of Pharmaceutical Industries and Associations) in June 2013 for a period of 2 years.

In addition to the Fireside Chats, the event also provides the opportunity to arrange meetings between investors, companies and industry business development, licensing and therapeutic franchise heads. One-on-one meetings will be powered by BIO One-on-One Partnering™, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors. This industry-specific, web-based interactive software enables participants to move efficiently from the identification of prospective partners to discussion and negotiations. 

Early bird registration ends December 16th. Qualified institutional and venture investors whose primary activity is direct investment in research and development companies are eligible for complimentary registration.  Equity research analysts from investment banking institutions also qualify as investors.  Media registration also is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.

BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors including supporting banks Leerink Swann and ROTH Capital Partners, LLC.


Upcoming BIO Events 

BIO CEO & Investor Conference
February 10 – 11, 2014
New York, NY

BIO Asia International Conference
April 8-9, 2014
Tokyo, Japan

World Congress on Industrial Biotechnology
May 12-15, 2014
Philadelphia, PA

BIO International Convention
June 23-26, 2014
San Diego, CA

Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD